Form 8-K - Current report:
SEC Accession No. 0001104659-23-025392
Filing Date
2023-02-24
Accepted
2023-02-24 17:25:11
Documents
17
Period of Report
2023-02-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm237532d3_8k.htm   iXBRL 8-K 31480
2 EXHIBIT 1.1 tm237532d3_ex1-1.htm EX-1.1 230235
3 EXHIBIT 5.1 tm237532d3_ex5-1.htm EX-5.1 7642
4 EXHIBIT 99.1 tm237532d3_ex99-1.htm EX-99.1 8075
5 EXHIBIT 99.2 tm237532d3_ex99-2.htm EX-99.2 8651
9 GRAPHIC tm237532d3_ex5-1.jpg GRAPHIC 12403
  Complete submission text file 0001104659-23-025392.txt   544193

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA apre-20230222.xsd EX-101.SCH 3024
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE apre-20230222_lab.xml EX-101.LAB 34476
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apre-20230222_pre.xml EX-101.PRE 22589
11 EXTRACTED XBRL INSTANCE DOCUMENT tm237532d3_8k_htm.xml XML 3606
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 267-370-5219
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39069 | Film No.: 23668782
SIC: 2834 Pharmaceutical Preparations